TP53 and acute myeloid leukemia: The increased killing efficacy of Reg−/− CAR T-cells was even more pronounced in TP53−/− cells, leading to comparable specific killing rates, and effectively overcoming the resistance of TP53-mutant AML cells against CAR T-cells at the investigated E:T range (Fig. 6G,H).